Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.
Angel Alsina, Masatoshi Kudo, Arndt Vogel, Ann‐Lii Cheng, Won Young Tak, Baek‐Yeol Ryoo, T.R. Jeffry Evans, Carlos López, Bruno Daniele, Soamnauth Misir, Min Ren, Namiki Izumi, Shukui Qin, Richard S. Finn (2019). Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.. , 37(4_suppl), DOI: https://doi.org/10.1200/jco.2019.37.4_suppl.371.
